Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Assessment of ALK

Assessment of ALK BRIEF REPORT Assessment of ALK Status by FISH on 1000 Spanish  Non-Small Cell Lung Cancer Patients Joana Vidal, MD,* Sergi Clavé, MSc,†‡ Silvia de Muga, PhD,§║ Iria González, MD,* Lara Pijuan, MD, PhD,║ Javier Gimeno, MD,║ Jordi Remón, MD,¶ Noemí Reguart, MD, PhD,# Nuria Viñolas, MD,# Regina Gironés, MD, PhD,** Laia Bernet, MD,** Margarita Majem, MD,†† Joaquim Bosch-Barrera, MD, PhD,‡‡ Rut Porta, MD, PhD,‡‡§§ Nieves Alonso, MD,║║ Ramón Palmero, MD,¶¶ Álvaro Taus, MD,* Joan Albanell, MD, PhD,*‡ Blanca Espinet, PhD,†‡ Marta Salido, PhD,†‡ and Edurne Arriola, MD, PhD,*‡ Conclusions: Although assessable in cytological samples, biopsies are Introduction: Patients with non-small cell lung cancer (NSCLC) preferred when available for ALK evaluation by FISH. The ALK trans- harboring anaplastic lymphoma kinase (ALK) rearrangement selec- location prevalence and the associated clinico-pathological features in tively respond to ALK inhibitors. Thus, identification of ALK rear - Spanish NSCLC patients are similar to those previously reported. rangements has become a standard diagnostic test in advanced NSCLC patients. Our institution has been a referral center in Spain Key Words: ALK, FISH, Non-small cell lung cancer, Biopsy, for ALK determination by Fluorescent in situ hybridization (FISH). Cytology. The aim of our study was to assess the feasibility and the FISH pat- (J Thorac Oncol. 2014;9: 1816–1820) terns of the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Assessment of ALK

Arriola, Edurne
Journal of Thoracic Oncology , Volume 9 (12) – Dec 1, 2014
Download PDF
5 pages

Loading next page...
 
/lp/wolters-kluwer-health/assessment-of-alk-KNgPV8U7PL

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN
1556-0864

Abstract

BRIEF REPORT Assessment of ALK Status by FISH on 1000 Spanish  Non-Small Cell Lung Cancer Patients Joana Vidal, MD,* Sergi Clavé, MSc,†‡ Silvia de Muga, PhD,§║ Iria González, MD,* Lara Pijuan, MD, PhD,║ Javier Gimeno, MD,║ Jordi Remón, MD,¶ Noemí Reguart, MD, PhD,# Nuria Viñolas, MD,# Regina Gironés, MD, PhD,** Laia Bernet, MD,** Margarita Majem, MD,†† Joaquim Bosch-Barrera, MD, PhD,‡‡ Rut Porta, MD, PhD,‡‡§§ Nieves Alonso, MD,║║ Ramón Palmero, MD,¶¶ Álvaro Taus, MD,* Joan Albanell, MD, PhD,*‡ Blanca Espinet, PhD,†‡ Marta Salido, PhD,†‡ and Edurne Arriola, MD, PhD,*‡ Conclusions: Although assessable in cytological samples, biopsies are Introduction: Patients with non-small cell lung cancer (NSCLC) preferred when available for ALK evaluation by FISH. The ALK trans- harboring anaplastic lymphoma kinase (ALK) rearrangement selec- location prevalence and the associated clinico-pathological features in tively respond to ALK inhibitors. Thus, identification of ALK rear - Spanish NSCLC patients are similar to those previously reported. rangements has become a standard diagnostic test in advanced NSCLC patients. Our institution has been a referral center in Spain Key Words: ALK, FISH, Non-small cell lung cancer, Biopsy, for ALK determination by Fluorescent in situ hybridization (FISH). Cytology. The aim of our study was to assess the feasibility and the FISH pat- (J Thorac Oncol. 2014;9: 1816–1820) terns of the

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Dec 1, 2014

There are no references for this article.